Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

GBI Research has released its latest research, “Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential”. The report provides insights into the up-and-coming trends of a portion of the acquired orphan blood disorder pharmaceutical market by examining Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), Paroxysmal Nocturnal Hemoglobinuria (PNH) and Polycythemia Vera (PV) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.

The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

The MF market will be the fastest growing of the five markets during the forecast period, at a Compound Annual Growth Rate (CAGR) of 34% and reaching a total market size of $1.1bn in 2019. MDS represents the largest market, expected to reach $2.2bn by 2019.

View full report with TOC:http://www.reportsandintelligence.com/acquired-orphan-blood-diseases-therapeutics-to-2019-search-for-disease-modifying-drugs-central-to-unlocking-premium-pricing-potential-market

Table Of Contents

1 Table of Contents

2 Acquired Orphan Blood Diseases - Introduction 

3 Acquired Orphan Blood Diseases - Therapeutic Landscape

3.1 Paroxysmal Nocturnal Hemoglobinuria 

3.1.1 Disease Overview 

3.1.2 Revenues 

3.1.3 Revenue Analysis by Country 

3.1.4 Annual Cost of Therapy 

3.1.5 Treatment Usage Patterns 

3.1.6 Marketed Products 

3.1.7 Market Drivers 

3.1.8 Market Restraints 

3.2 Paroxysmal Nocturnal Hemoglobinuria: Research and Development Pipeline 

3.2.1 Overview 

3.2.2 Trends in Paroxysmal Nocturnal Hemoglobinuria Pipeline 

3.2.3 Promising Pipeline Molecules 

3.2.4 Key Takeaway 

3.3 Idiopathic Thrombocytopenic Purpura 

3.3.1 Disease Overview 

4 Acquired Orphan Blood Diseases - Strategic Consolidations

5 Acquired Orphan Blood Diseases - Appendix 

Web Link:http://www.reportsandintelligence.com/